| Literature DB >> 30924321 |
Roberta Bottega1, Luisa M R Napolitano2, Anna Carbone3, Enrico Cappelli4, Fabio Corsolini5, Silvia Onesti2, Anna Savoia1,6, Paolo Gasparini1,6, Flavio Faletra1.
Abstract
BACKGROUND: Warsaw Breakage Syndrome (WABS) is an ultra rare cohesinopathy caused by biallelic mutation of DDX11 gene. It is clinically characterized by pre and postnatal growth delay, microcephaly, hearing loss with cochlear hypoplasia, skin color abnormalities, and dysmorphisms.Entities:
Keywords: DDX11; Warsaw Breakage Syndrome; mutations
Mesh:
Substances:
Year: 2019 PMID: 30924321 PMCID: PMC6503064 DOI: 10.1002/mgg3.639
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.183
Figure 3DDX11 alignment and 3D structure. (a) Multiple sequence alignment of eukaryotic DDX11 with the other human FeS cluster helicases. Residues conserved in most DDX11 sequences are highlighted in yellow. The mutated L836 residue is shown in red and indicated by a star. The predicted secondary structure is shown on the top (rectangular blue bar for α‐helix and purple arrows for β‐strands). (b) A DDX11 atomic model has been generated starting from XPD crystal structure (PDB ID: 4A15) with the ARCH domain in blue, HD1 and HD2 domains in two shades of green and the FeS cluster in orange. Unstructured regions/insertions in DDX11 are indicated in purple. The position of L836 is shown at the interface between the domains
Figure 1Clinical and cellular features. (a) Typical dysmorphisms observed in Warsaw Breakage Syndrome patients: bilateral epicanthal folds, upslanting palpebral fissures, prominent nose and columella with hypoplastic alae nasi, small ears, and micrognathia. (b) Trunk image showing the café‐au‐lait spots. (c) Comparison of the mitomycin C (MMC) induced cell survival analysis in LFB cells from a wild‐type (WT), patients carrying the DDX1 mutations (II‐1 and II‐2) and a Fanconi anemia patient carrying mutations in FANCA gene (FA‐A). WBS patients shows an intermediate phenotype. (d) Karyotype analyses after MMC induction
Figure 2Patients’ mutations and DDX protein expression. (a) Sanger sequencing validation of c.2507T > C (p.Leu836Pro) and (b) c.907_920del (p.Lys303Glufs*22) DDX11 mutations. (c) Pedigree of the family. (d) Western blot analyses of WBS patients (II‐1 and II‐2) showing a partial expression (22% and 23%, respectively) of DDX protein compared to wild type. HSP90 was used as loading control and normalizator for protein quantification